EPTRI is participating to the 6th edition of the RE(ACT) Congress and the 4th edition of the IRDiRC Conference that are taking places online from the 13th to be 15th of January 2021. It is organised by BLACKSWAN Foundation in collaboration with the European Joint Program Rare Diseases (EJP RD) and in partnership with Eurordis… Read More »
News
Last December 17th, EPTRI, the European Paediatric Translational Research Infrastructure, has sent an abstract entitled “EPTRI, a paediatric-dedicated research infrastructure to promote the availability of safer and efficacious drug for children” to the 40° Congress Italian Society of Pharmacology (SIF) that has been successfully accepted as oral communication. The main goal of this abstract is to… Read More »
The European Commission published the call “Call for expression of interest for expert panels on medical devices and in vitro diagnostic medical devices” to appoint experienced clinical, scientific and technical experts to scientific panels on medical devices. The experts to be selected needed to provide consistent scientific, technical and/or clinical advice on the implementation of… Read More »
Orphan and paediatric medicines share very similar challenges; however, some overlaps currently exist between the Regulation for medicines for rare diseases and the Regulation for medicines for children. EPTRI is participating in the EC Consultation on the revision of the Paediatric and Orphan Regulations (Ref. Inception Impact Assessment Ares (2020)7081640 – 25/11/2020) to promote more paediatric and orphan medicines and… Read More »
The European Joint Programme on Rare Diseases (EJP RD) has launched the EJP RD Joint Transnational Call (JTC) 2021 and will fund multilateral research projects on rare diseases under the EJP-COFUND action. EJP RD has successfully implemented two Joint Transnational Calls since 2019 to further help in coordinating the research efforts of European, Associated and… Read More »
On the 25th November 2020, the Commission adopted a “Pharmaceutical strategy for Europe” to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU’s pharmaceutical industry. EPTRI participated in the consultation phase underlining the necessity to stress new adequate health policies and actions promoting… Read More »
Last December 17th, an online event has been organised to present and disseminate the survey on Oral formulations and Administration Devices survey developed by EPTRI (European Paediatric Translational Research Infrastructure) and the EuFPI (European Paediatric Formulation Initiative). The webinar was addressed to all youths under the age of 18 who are also the target of... Read More »
View post
Dear Friends, this very challenging year is coming to an end and I would take this occasion to thank all of you for your continued collaboration and engagement that has allowed EPTRI to reach great achievements. As you know, EPTRI ended the design phase and just entered in the preparatory phase. We have also submitted… Read More »
On the 11th August 2020, the European Commission published its joint evaluation on the legislation on medicinal products for paediatric use and on orphan medicinal products. This is the first comprehensive evaluation of the two Regulations since their adoption in 2000 and 2006 respectively. They are evaluated together, given that the majority of rare diseases may… Read More »
The 8th Congress of the European Academy of Paediatric Societies (EAPS 2020) was held virtually on the 16th– 19th of October, 2020 and was organised by three societies: the European Academy of Paediatrics (EAP), the European Society for Paediatric Research (ESPR) and the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) with the eleven other European paediatric societies joining as collaborating... Read More »
View post